THJ-2201
THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.
It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
Pharmacology
THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at Cannabinoid [receptor type 1|CB1] and 1.32 nM at CB2 cannabinoid receptors.Side effects
THJ-2201 has been linked to at least one hospitalization and death due to its use.Legal status
It is classified as a Schedule I controlled substance in the United States.It is also an Drugs controlled by the [German Betäubungsmittelgesetz|Anlage II] controlled drug in Germany.